| 臺大學術典藏 |
2021-03-11T07:58:24Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:29:29Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; JIN-YUAN SHIH; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T04:37:07Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; JANN-YUAN WANG; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T02:50:52Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:03Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; LI-TA KENG; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-11-29T05:55:31Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang, Sheng-Kai; Keng, Li-Ta; Chang, Chia-Hao; Wen, Yueh-Feng; Lee, Meng-Rui; CHING-YAO YANG; Wang, Jann-Yuan; Ko, Jen-Chung; Shih, Jin-Yuan; Yu, Chong-Jen |
| 臺大學術典藏 |
2021-05-02T03:29:21Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-02-02T09:21:39Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen, Yueh Feng; MENG-RUI LEE; Yang, Ching Yao; JANN-YUAN WANG; JEN-CHUNG KO; JIN-YUAN SHIH; CHONG-JEN YU |
| 臺大學術典藏 |
2021-02-08T08:05:08Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Jen-Chung Ko;Sheng-Kai Liang;Li-Ta Keng;Chia-Hao Chang;Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu; JEN-CHUNG KO; SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu |
| 臺大學術典藏 |
2022-06-27T06:59:38Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; CHONG-JEN YU |
| 國立臺灣大學 |
2004 |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
李啟誠; 田蕙芬; 唐季祿; 姚明; 陳耀昌; 蘇益仁; 許世明; 洪瑞隆; LI, CHI-CHENG; TIEN, HWEI-FANG; TANG, JIH-LUH; YAO, MING; CHEN, YAO-CHANG; SU, IH-JEN; HSU, SU-MING; HONG, RUEY-LONG |
| 臺大學術典藏 |
2004 |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Hong R.-L.; Hsu S.-M.; Su I.-J.; Chen Y.-C.; Yao M.; Tang J.-L.; HWEI-FANG TIEN; Li C.-C. |
| 臺大學術典藏 |
2004 |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.; Tien H.-F.; Tang J.-L.; MING YAO; Chen Y.-C.; Su I.-J.; Hsu S.-M.; Hong R.-L. |
| 臺大學術典藏 |
2021-01-06T03:58:54Z |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.; Tien H.-F.; JIH-LUH TANG; Yao M.; Chen Y.-C.; Su I.-J.; Hsu S.-M.; Hong R.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:15Z |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.; Tien H.-F.; Tang J.-L.; Yao M.; YAO-CHANG CHEN; Su I.-J.; Hsu S.-M.; Hong R.-L. |
| 臺大學術典藏 |
2021-03-09T06:46:13Z |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.;Tien H.-F.;Tang J.-L.;Yao M.;Chen Y.-C.;Su I.-J.;Hsu S.-M.;Ruey-Long Hong; Li C.-C.; Tien H.-F.; Tang J.-L.; Yao M.; Chen Y.-C.; Su I.-J.; Hsu S.-M.; RUEY-LONG HONG |
| 國立臺灣大學 |
2006-09 |
Treatment outcome and patterns of failure in breast cancer patients with locoregional recurrence after mastectomy
|
Kuo, SH; Cheng, JC; Huang, CS; Kuo, WH; Chien, CR; Ting, LL; Cheng, AL; Chang, KJ; Lai, MK |
| 臺大學術典藏 |
2021-02-03T08:23:13Z |
Treatment outcome and patterns of failure in breast cancer patients with locoregional recurrence after mastectomy.
|
Kuo Sh;Chia-Hsien Cheng;Huang Cs;Kuo Wh;Chien Cr;Ting Ll;Cheng Al;Chang Kj;Lai Mk.; Kuo SH; CHIA-HSIEN CHENG; Huang CS; Kuo WH; Chien CR; Ting LL; Cheng AL; Chang KJ; Lai MK. |
| 國立成功大學 |
2023 |
Treatment outcome and prognostic factors analysis of carcinoma ex pleomorphic adenoma of major salivary glands
|
Chang, Y.-H.;Kuo, C.;Chang, T.-H.;Chen, M.-K.;Lin, J.-C. |
| 國立成功大學 |
2024-02 |
Treatment outcome and prognostic factors of external auditory canal squamous cell carcinoma: A retrospective study in a tertiary center
|
Huang;Yi-Ting;Wu;Jiunn-Liang;Chao;Wen-Yuan;Lee;Wei-Ting |
| 國立臺灣大學 |
2012 |
Treatment Outcome of Additional Dextran to Corticosteroid Therapy on Sudden Deafness: Propensity Score-Matched Cohort Analysis
|
Wang, Chi-Te; Chou, Hsu-Wen; Fang, Kai-Min; Lai, Mei-Shu; Cheng, Po-Wen; 賴美淑 |
| 國立成功大學 |
2020-03 |
Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy
|
Lee;Nan-Yao;Tsai;Chin-Shiang;Syue;Ling-Shan;Chen;Po-Lin;Li;Chia-Wen;Li;Ming-Chi;Ko;Wen-Chien |
| 國立成功大學 |
2020-03-01 |
Treatment Outcome of Bacteremia Due to Non–Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy
|
李南瑤; Lee, N.-Y.;Tsai, C.-S.;Syue, L.-S.;Chen, P.-L.;Li, C.-W.;Li, M.-C.;Ko, W.-C. |
